20-198 - Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis
Status: openA Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Patients with Relapsing Multiple Sclerosis
Description
Phase 3 clinical trial testing the safety and efficacy of a new drug for multiple sclerosis called evobrutinib
Sponsors
This trial is sponsored by Merck.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at +1 (251) 665-8375 or by email at dlwilliams@health.southalabama.edu.
Providers Associated With This Trial
Sub Investigators
This link will open in a new tab or window.